FDA Approves Toripalimab for Nasopharyngeal Carcinoma Treatment
The FDA has approved toripalimab, a PD-1 inhibitor developed by Junshi Biosciences, for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC) in the US market. Coherus BioSciences holds the rights for the drug in the US and Canada and plans to launch it under the brand name Loqtorzi in the first quarter of 2024.